Physician profile
Andrew Kim
NPI 1992790976
$22,672.87
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,658 · 2020: $3,005 · 2021: $4,272 · 2022: $4,391 · 2023: $3,767 · 2024: $3,579.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,272 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,271.66 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,735.44 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $3,545.86 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,158.10 | 2019-2024 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Abbvie INC. | $1,859.34 | 2019-2024 | |
| Insmed, INC. | $1,847.28 | 2019-2024 | Arikayce |
| Amgen INC. | $1,829.98 | 2019-2024 | Repatha, Evenity, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,571.06 | 2019-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $602.05 | 2019-2024 | Keytruda |
| Genzyme Corporation | $584.15 | 2020-2024 | |
| Philips North America LLC | $338.79 | 2019-2024 | (Ak6) Vest Therapy |
| Novo Nordisk INC | $337.77 | 2019-2024 | Ozempic, Rybelsus |
| Teva Pharmaceuticals USA, INC. | $279.80 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.66 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $265.09 | 2019-2020 | |
| Lilly USA, LLC | $228.99 | 2019-2023 | Jardiance, Mounjaro |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.